🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Adelaide
Clinical trial register · Australia

Clinical Trials in Adelaide, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Australia and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 3331 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:46 UTC
3331
Studies in scope
all four open statuses
1807
Recruiting now
open to new participants
758
Lead sponsors
across recruiting studies
Top sites
Melbourne 25 Adelaide 22 Brisbane 22 Box Hill 16 Perth 11
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Eli Lilly and Company22 Janssen Research & Development, LLC13 Novartis Pharmaceuticals13 BioNTech SE12 AstraZeneca12 Clear sponsor filter
Site location
Melbourne25 Adelaide22 Brisbane22 Box Hill16 Perth11
All 94 locations
Target enrolment
to

Trials with a site in Adelaide

22 of 3331 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Australia
Start
Recruiting
A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk
NCT07613294Atherosclerosis, Cardiovascular Diseases, Lipoprotein(a)
DrugLepodisiran
Eli Lilly and Company
Phase 3
252
Adelaide, Birtinya, Brisbane, Burwood, Joondalup, Leabrook, Merewether, Mulgrave
2026-06-01
Recruiting
A Study of LY3439539 in Participants With Alzheimer's Disease
NCT07598370Alzheimer Disease
Eli Lilly and Company
Phase 1
30
Adelaide, Ivanhoe, Kogarah, Macquarie University, Melbourne
2026-05-21
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
NCT07369011Sleep Apnea, Obstructive, Obesity, Overweight
DrugEloralintide
Eli Lilly and Company
Phase 3
800
Adelaide, Bedford Park, Box Hill, Brisbane, Heidelberg West, Maroochydore, Southport, Spearwood
2026-02-10
Recruiting
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
NCT07222332Diabetes Mellitus, Type 1
DrugBaricitinib
Eli Lilly and Company
Phase 3
300
Adelaide, Brisbane, Heidelberg West, Ipswich, Melbourne, Oaklands Park, Parkville, Perth
2026-02-05
Recruiting
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
NCT07222137Diabetes Mellitus, Type 1
DrugBaricitinib
Eli Lilly and Company
Phase 3
150
Adelaide, Box Hill, Brisbane, Melbourne, Parkville, Perth, Randwick, Westmead
2026-01-12
Recruiting
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
NCT07241390Atherosclerosis Cardiovascular Disease, Chronic Kidney Disease
DrugOrforglipron
Eli Lilly and Company
Phase 3
7,140
Adelaide, Blacktown, Box Hill, Brisbane, Bruce, Camberwell, Frankston, Garran
2025-12-01
Recruiting
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
NCT07165028Metabolic Dysfunction-Associated Steatotic Liver Disease
DrugsRetatrutide·Tirzepatide
Eli Lilly and Company
Phase 3
4,500
Adelaide, Box Hill, Brisbane, Broadmeadow, Geelong, Heidelberg, Ipswich, Murdoch
2025-10-15
Recruiting
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
NCT07157774Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Eli Lilly and Company
Phase 3
10,450
Adelaide, Box Hill, Brisbane, Burwood, Clayton, Frankston, Geelong, Greenfields
2025-09-02
Recruiting
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
NCT06876649Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
DrugPirtobrutinib
Eli Lilly and Company
Phase 4
787
Adelaide, Melbourne, Victoria
2025-05-20
Recruiting
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
NCT06876662Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
DrugPirtobrutinib
Eli Lilly and Company
Phase 4
279
Adelaide, Melbourne, Victoria
2025-05-20
Recruiting
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
NCT06439277Obesity, Weight Gain
DrugTirzepatide
Eli Lilly and Company
Phase 3
300
Adelaide, Coorparoo, Perth, Sydney
2024-06-03
Recruiting
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
NCT06400472Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Non-Small-Cell Lung
DrugsItraconazole·Bevacizumab·Carboplatin·Pembrolizumab
Eli Lilly and Company
Phase 1
575
Adelaide, QLD
2024-05-20
Active, closed
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
NCT06383390Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
DrugRetatrutide
Eli Lilly and Company
Phase 3
10,000
Adelaide, Botany, Box Hill, Brisbane, Brookvale, Camberwell, Garran, Geelong
2024-04-30
Active, closed
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
NCT06292013Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
DrugLepodisiran
Eli Lilly and Company
Phase 3
17,300
Adelaide, Blacktown, Botany, Box Hill, Brisbane, Bruce, Camberwell, Clayton
2024-03-05
Recruiting
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
NCT06119581Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
DrugsOlomorasib·Pemetrexed·Cisplatin·Carboplatin
Eli Lilly and Company
Phase 3
1,264
Adelaide, Auchenflower, Ballarat Central, Birtinya, Gosford, Mackay, Melbourne, Perth
2023-12-21
Active, closed
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
NCT05556512Obesity, Overweight
DrugTirzepatide
Eli Lilly and Company
Phase 3
15,374
Adelaide, Blacktown, Box Hill, Brisbane, Bruce, Camberwell, Clayton, Geelong
2022-10-11
Recruiting
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
NCT05307705Breast Cancer
DrugsAnastrozole, Exemestane·Imlunestrant·Abemaciclib·Letrozole
Eli Lilly and Company
Phase 1
260
Adelaide, East Melbourne, Sydney
2022-05-11
Active, closed
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
NCT04956640Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Endometrial Neoplasms, Ovarian Neoplasms
DrugsOlomorasib·Erbitux·Cetuximab·Pemetrexed
Eli Lilly and Company
Phase 1/2
540
St Leonards, Sydney, Adelaide, Frankston, Nedlands
2021-07-19
Active, closed
A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
NCT04232553Crohn's Disease
DrugMirikizumab
Eli Lilly and Company
Phase 3
996
Concord, Sydney, Brisbane, Maroochydore, Adelaide, Parkville, Murdoch
2020-06-22
Active, closed
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer
NCT04188548Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, Endometrial Cancer
DrugsImlunestrant·Alpelisib·Everolimus·Abemaciclib
Eli Lilly and Company
Phase 1
379
Darlinghurst, Waratah, Adelaide, Nedlands
2019-12-10
Active, closed
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
NCT03519945Ulcerative Colitis
DrugMirikizumab
Eli Lilly and Company
Phase 3
1,058
Adelaide, Box Hill, Brisbane, Maroochydore, Melbourne, Parkville
2018-07-18
Active, closed
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
NCT02711553Biliary Tract Cancer, Metastatic Cancer, Advanced Cancer
DrugsRamucirumab·Gemcitabine·Cisplatin
Eli Lilly and Company
Phase 2
309
Waratah, Adelaide, Heidelberg
2016-05-19
Rows per page Showing 1–22 of 22
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Australian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 29 September 2026. https://priyalifescience.com/clinical-trials-australia/city/adelaide

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Australia and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,331 studies in total at the last sync on 26 Sep 2026, 19:46 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 22 of those studies with a site in Adelaide that also match the filters currently applied.

How many clinical trials are recruiting in Adelaide?

14 of the 22 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:46 UTC sync. A further 0 have not yet opened recruitment, 8 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Adelaide), 22 studies
PhaseStudiesRecruitingShare
Phase 314963.6%
Phase 14318.2%
Phase 4229.1%
Phase 1/2104.5%
Phase 2104.5%

Most active sponsors

Lead sponsors with the most studies (Adelaide)
Lead sponsorStudiesRecruiting
Eli Lilly and Company2214
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.